Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578067 | 0.94 | CA14 (0.33) | MT-CO2NFKB1NFKB2RELACA14 | |
| SCHEMBL10389291 | 0.89 | NAMPT (0.33) | NFKB1NFKB2RELACA14 | |
| SCHEMBL2589188 | 0.88 | — | — | |
| SCHEMBL4595993 | 0.87 | CTSD (0.32) | MT-CO2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL23901170 | 0.85 | CA14 (0.36) | MT-CO2NFKB1NFKB2RELACA14 | |
| SCHEMBL13747089 | 0.85 | MT-CO2 (0.34) | MT-CO2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL11519549 | 0.85 | L3MBTL1 (0.36) | CA14 | |
| SCHEMBL10042568 | 0.83 | HDAC6 (0.32) | HDAC6HDAC1HDAC2 | |
| SCHEMBL417618 | 0.83 | NR1D1 (0.32) | — | |
| SCHEMBL6433493 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368100-B2 | Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1545498-A4 | BACKBONE-SUBSTITUTED BIFUNCTIONAL DOTA LIGANDS, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | US GOV HEALTH & HUMAN SERV (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060165600-A1 | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same | GOVERNMENT OF THE U.S.A., REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SVCS. (US) | 2006-07-27 | — | — | US | disclosed |
| US-7078013-B2 | Pretargeting methods and compounds | ALETHEON PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-6942966-B1 | libraries formed by permutations; combinatorial chemistry; drug screening | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1545498-A2 | BACKBONE-SUBSTITUTED BIFUNCTIONAL DOTA LIGANDS, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040241172-A1 | Pretargeting methods and compounds | NEORX CORPORATION (US) | 2004-12-02 | — | — | US | disclosed |
| EP-0906015-A4 | LIVER RETENTION CLEARING AGENTS | NEORX CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6709652-B2 | RADIOACTIVE LABELING OF BIOTIN | NEORX CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-5578287-A | COMPOUNDS FOR MEDICAL DIAGNOSIS AND TARGETS AND ANTIBODIES | NEORX CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0736035-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0732943-A1 | THREE-STEP PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5541287-A | DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS | NEORX CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995015335-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1995014493-A1 | THREE-STEP PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0646019-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1993025240-A2 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040241172-A1 | Pretargeting methods and compounds | HLCS, BTD, STRA6 | MT-CO2 4651/4885NFKB1 1353/4885NFKB2 2105/4885 |
| US-20060165600-A1 | Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same | UACA, PAICS, TBCA | MT-CO2 4152/4885NFKB1 3053/4885NFKB2 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.